Neoadjuvant chemotherapy has become the standard of care for breast cancer patients with large tumors in order to render them operable for mastectomy or, in some cases, for lumpectomy and radiation therapy. Building on this theme, several large hormonal therapies are extensively investigated in the neoadjuvant setting, together with biologic correlates for response and resistance. As a further extension, neoadjuvant therapies with biologic agents are now too, being investigated for biologic evidence of efficacy before large-scale clinical trials of thousands of patients are embarked on. The neoadjuvant setting is especially attractive for these studies for several reasons including early assessment of response to therapy, biopsiable access to the primary tumor, and considerable reduced sample sizes compared to those required in the adjuvant setting. In addition, clinical response to neoadjuvant chemotherapy is a validated surrogate marker for improved survival. It may be used to test the overall efficacy of neoadjuvant treatment regimens and mirrors the effect of therapy on micrometastases setting. In a recent study, good clinical response to neoadjuvant chemotherapy was the only independent variable, by multivariate analysis, associated with decreased risk of death.
GW572016 is a new and promising dual tyrosine kinase inhibitor against HER1/2. Hundreds of patients were treated in phase I and II studies world-wide and results indicate that this reversible, oral small molecule is generally well-tolerated. Studies of neoadjuvant Trastuzumab indicate that HER2 interference leads to significant tumor regression even after 3 weeks of monotherapy. We aim to extend these findings with a novel agent, GW572016 that may be more effective, especially from its in vitro data, and to discover the true response rate to inhibiting HER1/2 signal transduction in breast cancer patients.

Start Date31 Jul 2023

Sponsor / Collaborator

The University of New Mexico

NCT05400902

/ RecruitingPhase 2IIT

Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Bevacizumab in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Single-Center, Phase II Study

Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%. Surgical resection is the only curative method for ICC, but most patients are diagnosed at an advanced stage, and only 15% of patients can undergo surgical resection. In locally advanced ICC patients without distant metastases, although the tumor was initially assessed as unresectable, these patients may have the opportunity for surgical resection after reducing the size tumor lesion and increasing the remnant liver volume through conversion therapy. The current standard first-line treatment for unresectable ICC is gemcitabine combined with cisplatin, with a median overall survival of only 11.7 months and an ORR of 26.1%. In view of the poor effect of the standard chemotherapy regimen, the NCCN guidelines recommend that patients could participate in clinical study. Hepatic arterial infusion chemotherapy can increase the local blood drug concentration and improve the tumor regression rate. By reducing the dose of systemic chemotherapy drugs concentration, the incidence of adverse reactions can be reduced. Hepatic arterial infusion chemotherapy may be a better choice for locally advanced intrahepatic cholangiocarcinoma. PD-1 immunotherapy combined with targeted therapy is expected to improve the prognosis of patients with intrahepatic cholangiocarcinoma. This study investigates the safety and efficacy of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumabin the treatment of unresectable ICC.

Start Date31 May 2023

Sponsor / Collaborator

Sun Yat-Sen University

NCT05290116

/ RecruitingPhase 2IIT

Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Apatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Single-Center, Phase II Study

Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%. Surgical resection is the only curative method for ICC, but most patients are diagnosed at an advanced stage, and only 15% of patients can undergo surgical resection. In locally advanced ICC patients without distant metastases, although the tumor was initially assessed as unresectable, these patients may have the opportunity for surgical resection after reducing the size tumor lesion and increasing the remnant liver volume through conversion therapy. The current standard first-line treatment for unresectable ICC is gemcitabine combined with cisplatin, with a median overall survival of only 11.7 months and an ORR of 26.1%. In view of the poor effect of the standard chemotherapy regimen, the NCCN guidelines recommend that patients could participate in clinical study. Hepatic arterial infusion chemotherapy can increase the local blood drug concentration and improve the tumor regression rate. By reducing the dose of systemic chemotherapy drugs concentration, the incidence of adverse reactions can be reduced. Hepatic arterial infusion chemotherapy may be a better choice for locally advanced intrahepatic cholangiocarcinoma. PD-1 immunotherapy combined with targeted therapy is expected to improve the prognosis of patients with intrahepatic cholangiocarcinoma. This study investigates the safety and efficacy of hepatic arterial infusion chemotherapy combined with tislelizumab and apatinib in the treatment of unresectable ICC.

Start Date21 Jul 2022

Sponsor / Collaborator

Sun Yat-Sen University

100 Clinical Results associated with Lapatinib Ditosylate Hydrate

100 Translational Medicine associated with Lapatinib Ditosylate Hydrate

100 Patents (Medical) associated with Lapatinib Ditosylate Hydrate

3,205

Literatures (Medical) associated with Lapatinib Ditosylate Hydrate

01 Dec 2025·CANCER CHEMOTHERAPY AND PHARMACOLOGY

HER-2 SMASH

Article

Author: Şahin İnan, Zeynep Deniz ; Karaca, Mustafa ; Altun, Ahmet ; Yulak, Fatih ; Lacın, Burak Batuhan ; Öztürk, Ayşegül ; Alandağ, Celal

PURPOSE:

Human epidermal growth factor-2 (HER-2) targeted drugs are used in only HER-2 overexpressed cancers. However, only a small portion of these cancer types are HER-2 overexpressed. In this study, we aimed to upregulate HER-2 receptors in MCF-7 breast cancer and HT-29 colon cancer cell cultures, which these cells are not HER-2 upregulated in natural status.

METHODS:

We used a 10-day non-cytotoxic lapatinib dose to upregulate HER-2 receptors. HER-2 levels of these cell lines were tested with ELISA and immunofluorescence tests before and after 10 days of lapatinib administration. After upregulation of HER-2, we administered trastuzumab, and T-DM1 to these cell lines to observe whether there is an increase in anticancer activity. We used a cell viability test to show the cytotoxicity of trastuzumab and T-DM1. Also, we used ELISA and immunofluorescence for HER-2 pathway proteins to understand the mechanism of increased anti-cancer activity.

RESULTS:

We showed that administration of lapatinib for 10 days leads to overexpression of HER-2 receptors on both MCF-7 and HT-29 cells. A significant increase in the cytotoxicity of trastuzumab or T-DM1 was observed after 10 days of lapatinib administration.

CONCLUSION:

We named this method the smash method, which is the volleyball term. In volleyball, the ball is raised while low and quickly hits the ground again, just like we do with the HER-2 receptor. The smash method can switch HER-2 negative or HER-2 low tumors into HER-2 overexpressed, iatrogenically. Thus, we can use her2-targeted therapies in all cancer patients instead of a small portion.

01 Apr 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Chromatographic analysis and pKa evaluation of active pharmaceutical ingredients in anti-metastatic breast cancer: Green vs. conventional RPLC

Article

Author: Daldal, Yaşar Doğan ; Yilmaz, Hülya ; Kalkir, Fatmanur ; Demi Ralay, Ebru Çubuk

This study aimed to determine the chromatographic retention and dissociation/protonation constant (pK_a) values of lapatinib and tamoxifen, key drugs used in metastatic breast cancer treatment, at 37°C using both conventional and green high-performance liquid chromatography (HPLC) methods. Qualitative analysis was conducted on an XTerra C18 column (250 ×4.6 mm I.D., 5 μm particle size) at a flow rate of 1 mL/min. Hydroorganic mixtures with 45 %, 50 %, 55 %, and 60 % (v/v) organic modifiers were used to evaluate the retention times of the compounds. The compatibility of pK_a values pKass of the compounds in water-organic solvent mixtures obtained from these studies, which were carried out without any significant change in liquid chromatography performance, with the values obtained by the conventional method is remarkable. The pKass values determined in this study were correlated with the macroscopic parameters of acetonitrile, methanol, ethanol and the pK_a (pKaww)values of lapatinib and tamoxifen in water were calculated. The pKaww values calculated from these studies are compatible with each other and with the literature values. The environmental impact of the study, which was carried out using the green method and the conventional RPLC method, was evaluated using the Green Solvent Selection Tool (GSST), Green Analytical Procedures Index (GAPI), and Analytical Greenness Metric Approach (AGREE).

01 Mar 2025·COLLOIDS AND SURFACES B-BIOINTERFACES

Combination therapy of Lapatinib/Letrozole-based protein-vitamin nanoparticles to enhance the therapeutic effectiveness in drug-resistant breast cancer

Article

Author: Biswas, Swati ; Das, Sneha ; Are, Varshini ; P S, Shishira

HER2-positive breast cancer constitutes 20 % of reported cases, characterized by excessive expression of HER2 receptors, pivotal in cell signaling and growth. Immunotherapy, the established treatment, often leads to multidrug resistance and tumor recurrence. There's a critical need for an effective strategy delaying drug resistance onset and ensuring cancer cell eradication. This study aimed to develop nanoparticles using human serum albumin (HSA) coupled with vitamin E (α-tocopherol succinate), loaded with a tyrosine kinase inhibitor (TKI) or aromatase inhibitor (AI). Nanoparticles were formed via desolvation, where HSA(VE) conjugates self-organized into a nanoparticle structure, incorporating TKI/AI either through chemical conjugation or direct binding to HSA. Physico-chemical analyses-such as infrared spectroscopy (IR), gel permeation chromatography (GPC), UV, IR, and CD spectroscopy confirmed HSA(VE) binding and drug incorporation into nanoparticles, evaluating their drug entrapment, release efficiency. Cell viability assays and in-vitro experiments on resistant and sensitive cell lines demonstrated effective drug encapsulation and absorption over time. Both in vitro and in vivo studies demonstrated that a combination of Lapa@HSA(VE) NPs and Let@HSA(VE) NPs in the ratio 75:25 inhibited tumor development and enhanced apoptosis significantly compared to individual NP treatment and free drug. The combination NPs therapy exhibited significant efficacy even in Lapa-resistant cell lines.

News (Medical) associated with Lapatinib Ditosylate Hydrate

13 Dec 2024

·endpts.com

Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M milestone

Plus, news about Candel, Inovio and RemeGene: Eisai licenses Newron Pharmaceuticals’ evenamide: Eisai’s subsidiary EA Pharma will pay up to €117 million ($123 million) in upfront and milestone fees for rights to the treatment-resistant schizophrenia therapy in Japan and other Asian territories. Newron will continue development elsewhere, with a pivotal trial of the glutamate modulator as an add-on therapy to antipsychotics to start next year. — Elizabeth Cairns Novavax earns a milestone: The Maryland vaccine maker received the first $50 million biobuck payment from Sanofi as part of the pact they announced in May . — Kyle LaHucik Candel priced its $80 million offering at $6 per share $CADL following Phase 3 data earlier this week, and Inovio priced its $30 million offering to fund its DNA medicines. — Kyle LaHucik RemeGen’s ADC succeeds in Phase 3 : Data presented at the San Antonio Breast Cancer Symposium showed disitamab vedotin yielded a 44% reduction in the risk of progression or death in patients with HER2-positive advanced breast cancer with liver metastasis, versus Novartis’ Tykerb plus capecitabine. Progression-free survival with the HER2-targeting conjugate was 9.9 months versus 4.9 months with the Tykerb combo. The company described the PFS benefit as “clinically meaningful”. — Elizabeth Cairns

VaccinePhase 3Clinical Result

12 Dec 2024

·www.prnewswire.com

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasis (BCLM). This is the first prospective randomized phase III study globally on a HER2-targeting ADC that demonstrated significant efficacy in patients with HER2-positive advanced BCLM. Professor Jiayu Wang from the Cancer Hospital, Chinese Academy of Medical Sciences presented and discussed the study. SABCS is one of the largest and most influential annual conferences focusing on advances in breast cancer clinical research, and this RemeGen sponsored study attracted the attention of experts worldwide. Data shows that about 45% of patients with HER2-positive advanced breast cancer have liver metastasis. This subset has a poor prognosis with a 5-year survival rate of only 8% to 12%, for whom no satisfactory therapies are available now. This is a randomized, open-label, multicenter phase III study comparing the efficacy and safety of DV versus Lapatinib plus Capecitabine in patients with HER2-positive advanced BCLM. A total of 104 patients were enrolled, of whom 53 received DV and 50 received Lapatinib plus Capecitabine. All patients had previously been treated with Trastuzumab and Taxanes. As of data cutoff date (December 31, 2023), according to the assessment by the Independent Review Committee (IRC), DV significantly improved progression-free survival (PFS) versus Lapatinib plus Capecitabine (median: 9.9 months vs. 4.9 months; hazard ratio [HR]: 0.56 [95% CI: 0.35-0.90]), which is consistent with the investigator-assessed PFS (HR: 0.62 [95% CI: 0.39-0.98]). The overall survival (OS) data, though immature, indicated a benefit trend in favor of DV. The safety profile was consistent with past DV use experience, with no new safety signals detected. "This is the first confirmatory phase III study that demonstrated promising efficacy of an HER2-targeting ADC in patients with HER2-positive advanced BCLM," observed Professor Jiayu Wang. DV demonstrated clinically meaningful benefit compared with Lapatinib plus Capecitabine and a manageable safety profile, potentially offering a promising new treatment option for patients with HER2-positive advanced BCLM previously treated with Trastuzumab and Taxanes. The Biologics License Application (BLA) filing for this indication of DV has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration in October 2024 and priority review was granted based on the breakthrough therapy designation. SOURCE RemeGen Co., Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Clinical ResultBreakthrough TherapyPriority ReviewADC

09 Aug 2024

·www.fda.gov

FDA approves neratinib for metastatic HER2-positive breast cancer

On February 25, 2020, the Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. Efficacy of neratinib with capecitabine was investigated in NALA (NCT01808573), a randomized, multicenter, open-label clinical trial in 621 patients with metastatic HER2-positive breast cancer who received two or more prior anti-HER2 based regimens in the metastatic setting. Patients were randomized (1:1) to receive neratinib 240 mg orally once daily on days 1-21 with capecitabine 750 mg/m2 given orally twice daily on days 1-14 for each 21-day cycle (n=307) or lapatinib 1250 mg orally once daily on days 1-21 with capecitabine 1000 mg/m2 given orally twice daily on days 1-14 for each 21-day cycle (n=314). Patients were treated until disease progression or unacceptable toxicity. The primary efficacy outcome measures were progression-free survival (PFS), assessed by a blinded independent central review per RECIST v1.1, and overall survival (OS). Key secondary outcome measures were objective response rate (ORR) and response duration. Median PFS was 5.6 months (95% CI: 4.9, 6.9) for patients who received neratinib with capecitabine and 5.5 months (95% CI: 4.3, 5.6) for those receiving lapatinib with capecitabine (hazard ratio 0.76; 95% CI: 0.63, 0.93; p=0.0059). The PFS rate at 12 months was 29% (95% CI: 23, 35) vs 15% (95% CI: 10, 20), respectively. Median OS was 21 months (95% CI: 17.7, 23.8) for patients receiving neratinib with capecitabine compared to 18.7 months (95% CI: 15.5, 21.2) for those receiving lapatinib plus capecitabine (HR 0.88; 95% CI: 0.72, 1.07; p=0.2086). The ORR was 32.8% (95% CI: 27.1, 38.9) vs 26.7% (95% CI: 21.5, 32.4), respectively. Median response duration was 8.5 (95% CI: 5.6, 11.2) vs 5.6 months (95% CI: 4.2, 6.4), respectively. The most common adverse reactions of any grade (>5%) in the neratinib plus capecitabine arm were diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms. The most frequently reported Grade 3 or 4 adverse reactions were diarrhea, nausea, vomiting, fatigue and decreased appetite. The recommended neratinib dose for advanced or metastatic breast cancer is 240 mg (6 tablets) given orally once daily with food on days 1-21 of a 21-day cycle plus capecitabine (750 mg/m2 given orally twice daily) on days 1-14 of a 21-day cycle until disease progression or unacceptable toxicities. View full prescribing information for NERLYNX. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was approved 2 months prior to the FDA goal date. Neratinib was granted Fast Track designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on Twitter @FDAOncologyExternal Link Disclaimer. Content current as of: 02/26/2020 Regulated Product(s) Drugs 02/26/2020 Drugs Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Clinical ResultAccelerated ApprovalFast TrackDrug Approval

100 Deals associated with Lapatinib Ditosylate Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lapatinib Ditosylate Hydrate	L01XE07	DB01259

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic breast cancer	US	Novartis Pharmaceuticals Corp.	29 Jan 2010
HER2 Positive Breast Cancer	CH	Novartis AG	23 May 2007
Breast Cancer	US	Novartis Pharmaceuticals Corp.	13 Mar 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ER-positive/HER2-positive Breast Cancer	Phase 3	JP	GlaxoSmithKline (China) Investment Co., Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	JP	Glaxo Group Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	AR	Glaxo Group Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	AR	GlaxoSmithKline (China) Investment Co., Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	BE	GlaxoSmithKline (China) Investment Co., Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	BE	Glaxo Group Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	FR	GlaxoSmithKline (China) Investment Co., Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	FR	Glaxo Group Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	GR	Glaxo Group Ltd.	05 May 2011
ER-positive/HER2-positive Breast Cancer	Phase 3	GR	GlaxoSmithKline (China) Investment Co., Ltd.	05 May 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_GI2024 Manual	Not Applicable	HER2 positive Biliary Tract Neoplasms Second line HER2 Positive	21	Trastuzumab plus lapatinib	uvaorojhja(hhuyarpvkv) = jsrbzaolxk fufqvvjskf (dwlrazbxoo, 28.6 - 57.1) View more	Positive	27 Jun 2024
NCT01619111 (DETECT III, Pubmed) Manual	Phase 3	HER2-negative breast cancer \| Circulating Neoplastic Cells HER2 Negative \| HER2 Positive	101	LapatinibLapatinib	vheraoyxqp(vuetdzevzh) = itukjcdvfh wiqzfzzpnj (ccoubsvqbp ) View more	Positive	04 Jan 2024
				Standard therapy	vheraoyxqp(vuetdzevzh) = ldhucjjmqh wiqzfzzpnj (ccoubsvqbp ) View more
ESMO2023 Manual	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2 positive	53	lapatinib or pyrotinib	lrvegvcjkw(auwagvkvza) = rbavzctfpn ixykusouna (pumvtbaotg, 7.9 - 15.9) View more	Positive	21 Oct 2023
				lapatinib or pyrotinib (brain metastasis)	lrvegvcjkw(auwagvkvza) = lwgwdpzuye ixykusouna (pumvtbaotg, 7.5 - 13.5) View more
NCT01485926 (ICORG/CTRIAL-IE 10-05, SABCS2023)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2+	76	TCH	oyxaeujaqz(oginevirva) = vfcqddieqj jpipljjxdr (plhmojwqrs ) View more	Negative	01 Mar 2023
				TCHL	oyxaeujaqz(oginevirva) = bawibpyyej jpipljjxdr (plhmojwqrs ) View more
ESMO_ASIA2022	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast	47	Low dose or metronomic lapatinib (500mg daily with meal)	zmhkmvbdua(xwpqfqzilb) = wrrogpbkvr orybsuchrg (gknupwjgzl ) View more	-	03 Dec 2022
Pubmed Manual	Not Applicable	HER2-positive gastric cancer Third line HER2-Positive	59	Lapatinib Ditosylate Hydrate	mleyygxdnk(qcktzjwnpl) = tptoacowfd apiwmdlzbq (byzbormqdi ) View more	Positive	01 Oct 2022
ASCO2022	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast	102	Lapatinib and capecitabine combination	oepfzpyadl(bgpwfpltad) = vqftaworga cseykusgax (icrtqqsvwh, 5.1 - 10.8)	-	02 Jun 2022
Pubmed Manual	Phase 2	Thymic Epithelial Tumor	25	Lapatinib Ditosylate Hydrate	uixlmkekug(casdqeugvy) = xffiurkuto qvoqmcfrxw (odycnjevlu, 21 - 61) View more	Positive	10 May 2022
NCT00470704 (TBCRC003 \| TBCRC 003, CTgov)	Phase 2	HER2 Positive Breast Cancer	87	Herceptin+Lapatinib (Cohort 1)	pehauqakhq(culvzjlkyk) = tufhwwzggz jrwrctbvnp (flcxtnzdam, qtbdemawja - patzgnbtmf) View more	-	15 Mar 2022
				Herceptin+Lapatinib (Cohort 2)	pehauqakhq(culvzjlkyk) = twctdfwiej jrwrctbvnp (flcxtnzdam, rnpfhxfodq - wpdqvgytrv) View more
P2-13-36 (SABCS2022)	Not Applicable	HER2-positive	-	Neratinib	yappkqbbhp(bpafypqpby) = 50 nM neratinib induced higher activation of caspase 3/7 than 500 nM lapatinib or 500 nM tucatinib xrwlefempn (ysswwmukmk ) View more	-	15 Feb 2022
				Lapatinib

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis